Presentation is loading. Please wait.

Presentation is loading. Please wait.

Structural and population pharmacokinetic properties (single drug) of BRAF indicator dabrafenib, vemurafenib and encorafenib and of MEK indicator trametinib,

Published byJanusz Piotrowski Modified over 5 years ago

Similar presentations

Presentation on theme: "Structural and population pharmacokinetic properties (single drug) of BRAF indicator dabrafenib, vemurafenib and encorafenib and of MEK indicator trametinib,"— Presentation transcript:

1 Structural and population pharmacokinetic properties (single drug) of BRAF indicator dabrafenib, vemurafenib and encorafenib and of MEK indicator trametinib, cobimetinib and binimetinib. Structural and population pharmacokinetic properties (single drug) of BRAF indicator dabrafenib, vemurafenib and encorafenib and of MEK indicator trametinib, cobimetinib and binimetinib. AR, accumulation ratio; AUC 0–24, area under the curve for 0–24 h (AUC 0–8 : 0-8 h); BCS, biopharmaceuticsclassification system; C max, maximum concentration; C 24, concentration after 24 h; d, days; h, hours; MTD,maximum tolerated dose; od, once daily; RP2D, recommended phase 2 dose; t 1/2 eff, effective half-life,calculated as –0.693*tau/(ln[1–{1/AR}]); td, twice daily; t max, time taken to reach maximum concentration,reported as median. In brackets: (%CV b), between-subject coefficient of variation; (nc), not calculated; (nr),not reported; […], range. All reported values are means, if not indicated otherwise (i.e. median). Lucie Heinzerling et al. ESMO Open 2019;4:e000491 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "Structural and population pharmacokinetic properties (single drug) of BRAF indicator dabrafenib, vemurafenib and encorafenib and of MEK indicator trametinib,"

Similar presentations

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Rivaroxaban: A Comparison of Once- and Twice-daily Dosing in Patients Undergoing Total Hip Replacement.

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Rivaroxaban: A Comparison of Once- and Twice-daily Dosing in Patients Undergoing Total Hip Replacement.
The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.
Comparison of the model incorporating daily dose to that incorporating Cmax. Comparison of the model incorporating daily dose to that incorporating Cmax.

Comparison of the model incorporating daily dose to that incorporating Cmax. Comparison of the model incorporating daily dose to that incorporating Cmax.
Braf-MUTATION POSITIVE melanoma: a case conference

Braf-MUTATION POSITIVE melanoma: a case conference
Activity Goals. Activity Goals Program Overview.

Activity Goals. Activity Goals Program Overview.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.

Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
Progesterone receptor nuclear morphology patterns in breast cancer.

Progesterone receptor nuclear morphology patterns in breast cancer.
Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.
Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.
Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.
Flow chart of the used methodology adapted from Moher et al

Flow chart of the used methodology adapted from Moher et al
The decision tree with the two alternatives.

The decision tree with the two alternatives.
Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.

Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
Plasma concentration–time profile, relative bioavailability and pharmacokinetic (PK) parameters of 4 mg TAK-228 in the single-agent QD PK run-in period,

Plasma concentration–time profile, relative bioavailability and pharmacokinetic (PK) parameters of 4 mg TAK-228 in the single-agent QD PK run-in period,
PRISMA study flow diagram

PRISMA study flow diagram
M.R. Jacobs  Clinical Microbiology and Infection 

M.R. Jacobs  Clinical Microbiology and Infection 

Similar presentations

Ads by Google